CELL & GENE THERAPY INSIGHTS

Download issue

May 2020. Vol 6 Issue 4

May 2020

FEATURING

Issue Spotlight: Trends and advances in gene therapy delivery and gene editing
Reports: Innovation Insights May 2020 | Commercial Insights March 2020

Webinar

Spotlight

Trends and advances in gene therapy delivery and gene editing
May 2020

Expert Insight

Polymer nanoparticles: potential for efficient, biodegradable, and cost-effective delivery of gene therapy to multiple tissues

Polymer nanoparticles: potential for efficient, biodegradable, and cost-effective delivery of gene therapy to multiple tissues
Timothy Fong,
Steven Bodovitz,
Kunwoo Lee
14 May 2020
Expert Insight
Read more
High dose systemic gene therapy: emerging trends on safety and efficacy

High dose systemic gene therapy: emerging trends on safety and efficacy
Hansell Stedman,
Roland Herzog,
Guangping Gao,
George Church,
Ying Kai Chan
6 May 2020
Expert Insight
Read more

Innovator Insight

FectoVIR<sup>®</sup>-AAV: a giant step for AAV large scale manufacturing

FectoVIR®-AAV: a giant step for AAV large scale manufacturing
Alengo Nyamay'antu,
Malik Hellal,
Mathieu Porte ,
Patrick Erbacher
28 May 2020
Innovator Insight
Read more

Interview

A return to rational capsid design? Predicting the future of AAV vector R&D

A return to rational capsid design? Predicting the future of AAV vector R&D
R Jude Samulski
10 June 2020
Interview
Read more
Next steps in targeting the CNS with AAV-driven gene therapy

Next steps in targeting the CNS with AAV-driven gene therapy
Bruce Goldsmith
14 May 2020
Interview
Read more
Gene editing as a key enabler of allogeneic cell therapy

Gene editing as a key enabler of allogeneic cell therapy
Torsten Meissner
4 May 2020
Interview
Read more
Precise and non-disruptive gene editing based on programmable nickases

Precise and non-disruptive gene editing based on programmable nickases
Manuel Goncalves
23 April 2020
Interview
Read more

Report

Innovation Insights May 2020

Editorial

Exosome-based therapeutics: ready for prime time

Exosome-based therapeutics: ready for prime time
Konstantin Konstantinov,
Jonathan Finn
20 May 2020
Editorial
Read more

Commentary

Exosomes at scale as next-generation cell free medicines: fact and fiction

Exosomes at scale as next-generation cell free medicines: fact and fiction
Ian Dixon
20 May 2020
Commentary
Read more

Interview

An educated approach: AI-enabled neoantigen vaccine R&D

An educated approach: AI-enabled neoantigen vaccine R&D
Roman Yelensky
14 May 2020
Interview
Read more

Report

Commercial Insights March 2020

Cell & Gene Therapy Commercial Insight - March 2020

Cell & Gene Therapy Commercial Insight - March 2020
Mark Curtis,
Richard Philipson
23 May 2020
Read more

Webinars

Enabling the industrialization of human induced pluripotent stem cell-based therapies

Enabling the industrialization of human induced pluripotent stem cell-based therapies
Krishna Panchalingam
Krishna Panchalingam, Bioprocess Scientist at Lonza Pharma & Biotech
Inbar Friedrich Ben-Nun
Inbar Friedrich Ben-Nun, Senior Manager at Lonza Pharma & Biotech
Marcos Langtry
Marcos Langtry, Head of Allogeneic Cell Therapy Commercial Development, Lonza Pharma & Biotech
4 June 2020
Webinar
Watch now